Navigation Links
Teva and Barr Provide Update on Acquisition
Date:10/27/2008

er and any other relevant documents carefully in their entirety because they contain important information about the proposed transaction. The registration statement containing the proxy statement/prospectus and other documents is available free of charge at the SEC's website, http://www.sec.gov. You may also obtain the proxy statement/prospectus and other documents free of charge by contacting Barr Investor Relations at 201-930-3720 or Teva Investor Relations at 972-3-926-7554 / 215-591-8912.

Teva, Barr and their respective directors and executive officers and other members of management and employees may be deemed to participate in the solicitation of proxies in respect of the proposed transaction. Information regarding Barr's directors and executive officers is available in Barr's proxy statement for its 2007 annual meeting of stockholders, which was filed with the SEC on May 15, 2008 and information regarding Teva's directors and executive officers is available in Teva's Annual Report on Form 20-F for the year ended December 31, 2007, which was filed with the SEC on February 29, 2008. Additional information regarding the interests of such potential participants will be included in the proxy statement/prospectus and the other relevant documents filed with the SEC.


'/>"/>
SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
2. LI-COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging
3. HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City
4. Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC
5. Netsmart Technologies Selected by City and County of San Francisco to Provide Integrated Behavioral Healthcare Software System
6. China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
7. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
8. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
9. The Plasmodium vivax genome provides new routes and challenges in the global fight against malaria
10. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
11. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... HOUSTON, TX and VANCOUVER ... or the "Company") (TSX-V: EPI) announced today that it ... in the US an Investigation New Drug ("IND") application ... in prostate cancer patients.  Approval of the IND application ... testing of EPI-506 in the US.  ...
(Date:3/31/2015)... 31, 2015  Sonoa Health, a health tech startup ... developed a world-first consumer health portal, Health&, which brings ... devices and more. Today, the Company appointed ... CEO, who brings to the table more than 18-years ... included working closely with the biggest names in Silicon ...
(Date:3/31/2015)... NEW YORK , March 31, 2015 /PRNewswire/ ... biopharmaceutical company advancing protein biologic therapies and oncology ... marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") (KSE: ... the country,s Ministry of Food and Drug Safety ... (KTR) for MuGard, its oncology supportive-care treatment for ...
(Date:3/31/2015)... 31, 2015 Diasome Pharmaceuticals, Inc. ( ... Inc., that a United States patent has recently been ... , Entitled “Lipid Construct for Delivery of ... matter claims related to the use of Diasome’s proprietary ... injected insulin to more effectively reach the liver’s metabolic ...
Breaking Biology Technology:ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 3ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 4Investment Banker Appointed CEO of Australian Health Tech Start-Up 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 3PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2
... Earlier Identification of Toxicity, Efficacy for Pharmaceutical ... ... CITY, Calif., Aug. 29 Codexis, Inc., a private,biotechnology company ... licensed important intellectual property,from the California Institute of Technology for ...
... Corporation,(Nasdaq: DRRX ) announced today that James ... the NewsMakers in the Biotech Industry Investment,Conference to ... 6, 2007 at 11:30 a.m.,Eastern Time. (Logo: ... of the presentation will be available by accessing,DURECT,s ...
... Pharmion Corporation,(Nasdaq: PHRM ) today announced that ... Fast Track designation for oral Azacitidine in the,treatment ... are designed to facilitate the development and,expedite the ... treat serious or,life-threatening conditions and that demonstrate the ...
Cached Biology Technology:Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are ...
(Date:3/18/2015)... Florida , March 18, 2015 ... as businesses, new revolutionary smart wallets and apps continue to ... Companies currently entrenched in the mobile payment industry in focus ... Group Holding Ltd. (NYSE: BABA ), Apple Inc. ... GOOG ) and Facebook Inc. (NASDAQ: FB ) ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... known as Ecstasy, can reverse the symptoms of Parkinson's ... condition, according to new research at Duke University Medical ... animals do not suggest Parkinson's disease patients should find ... with many dangerous side effects. The findings rather indicate ...
... how the immune system reacts to strains of ... healthy people, or so-called "community-acquired" infections--has shown for ... deadly and better at evading human immune defenses ... in hospitals and other health-care settings. , In ...
... further evidence that one of the oldest biological laws ... sump tank reservoirs of machines in an engineering workshop ... Microbiology. , Scientists from the Centre for Ecology & ... abundance and genetic diversity of bacteria living in oil-based ...
Cached Biology News:Amphetamines reverse Parkinson's disease symptoms in mice 2Amphetamines reverse Parkinson's disease symptoms in mice 3Amphetamines reverse Parkinson's disease symptoms in mice 4Emerging staph strains found to be increasingly deadly and deceptive 2Emerging staph strains found to be increasingly deadly and deceptive 3Applying ecological laws to bacteria 2
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Mycoplasma tested...
Recombinant Human PTP1B (aa 2-321), CF...
Biology Products: